Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 614-617

  Jensen, Rasmus Hare ^a   Johansen, Helle Krogh ^b   Arendrup, Maiken Cavling ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; FKS1P PROTEIN; FLUCONAZOLE; POSACONAZOLE; PROTEIN; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA TROPICALIS; CANDIDIASIS; CASE REPORT; CLONAL VARIATION; EPSILOMETER TEST; FUNGAL DETECTION; FUNGUS CULTURE; FUNGUS ISOLATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; CANDIDA TROPICALIS; CANDIDIASIS; CLONE CELLS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HOMOZYGOTE; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROLINE; SEQUENCE ANALYSIS, DNA; SERINE;

EID: 84872044632     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01193-12     Document Type: Article

References (40)

1. Baixench M-T, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, Piketty C, Dannaoui E. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
2. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
3. Costa-de-Oliveira S, Marcos Miranda I, Silva RM, Pinto E Silva A, Rocha R, Amorim A, Gonçalves Rodrigues A, Pina-Vaz C. 2011. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob. Agents Chemother. 55:1312-1314.
4. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
5. Durán-Valle MT, Gago S, Gómez-López A, Cuenca-Estrella M, Jiménez Díez-Canseco L, Gómez- Garcés JL, Zaragoza O. 2012. Recurrent episodes of candidemia due to Candida glabrata with a mutation in the hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob. Agents Chemother. 56:3417-3419.
6. Garcia-Effron G, Chua DJ, Tomada JR, DiPersio J, Perlin DS, Ghannoum M, Bonilla H. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227.
7. Sun H-Y, Singh N. 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35:211-218.
8. Arendrup MC, Fuursted K, Gahrn-Hansen B, Schønheyder HC, Knudsen JD, Jensen IM, Bruun B, Christensen JJ, Johansen HK. 2008. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487-494.
9. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Møller J, Nielsen L, Rosenvinge FS, Røder B, Schønheyder HC, Thomsen MK, Truberg K. 2011. National surveillance of fungemia in Denmark (2004 to 2009). J. Clin. Microbiol. 49:325-334.
10. Chai LYA, Denning DW, Warn P. 2010. Candida tropicalis in human disease. Crit. Rev. Microbiol. 36:282-298.
11. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48:1366-1377.
12. Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Shimono N, Kamimura T, Akashi K. 2012. Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies. J. Infect. Chemother. In press.
13. Kothavade RJ, Kura MM, Valand AG, Panthaki MH. 2010. Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. J. Med. Microbiol. 59:873-880.
14. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. 2009. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn. Microbiol. Infect. Dis. 65:27-34.
15. Yang Y-L, Lin C-C, Chang T-P, Lauderdale T-L, Chen H-T, Lee C-F, Hsieh C-W, Chen P-C, Lo H-J. 2012. Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole. PLoS One 7:e34609. doi:10.1371/journal.pone.0034609.
16. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-247.
17. Arendrup MC, Garcia-Effron G, Buzina W, Mortensen KL, Reiter N, Lundin C, Jensen HE, Lass-Flörl C, Perlin DS, Bruun B. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
18. Arendrup MC, Rodriguez-Tudela J-L, Park S, Garcia-Effron G, Delmas G, Cuenca-Estrella M, Gomez-Lopez A, Perlin DS. 2011. Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob. Agents Chemother. 55:1580-1587.
19. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. 2012. The presence of an FKS mutation rather thanMICis an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 56:4862-4869.
20. Arendrup MC, Rodriguez-Tudela J-L, Lass-Flörl C, Cuenca-Estrella M, Donnelly JP, Hope W. 2011. EUCAST technical note on anidulafungin. Clin. Microbiol. Infect. 17:E18-20.
21. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
22. Arendrup MC, Pfaller MA. 2012. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56:3965-3968.
23. Tavanti A, Davidson AD, Johnson EM, Maiden MCJ, Shaw DJ, Gow NAR, Odds FC. 2005. Multilocus sequence typing for differentiation of strains of Candida tropicalis. J. Clin. Microbiol. 43:5593-5600.
24. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O, French Mycoses Study Group. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg. Infect. Dis. 18:86-90.
25. Hernandez S, Lo L, Najvar LK, Mccarthy DI, Bocanegra R, Graybill JR. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
26. Laverdière M, Lalonde RG, Baril J-G, Sheppard DC, Park S, Perlin DS. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
27. Park S, Kelly R, Kahn JN, Robles J, Hsu M, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
28. Daneman N, Chan AK, Poutanen SM, Rennie R, Sand C, Porter S. 2006. The emergence of caspofungin resistance during treatment of recurrent Candida glabrata candidaemia. Clin. Microbiol. Infect. 12:P1204.
29. Dodgson KJ, Dodgson AR, Pujol C, Messer SA, Soll DR, Pfaller MA. 2005. Caspofungin resistant C. glabrata. Clin. Microbiol. Infect. 11:P1158.
30. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
31. Singh-Babak SD, Babak T, Diezmann S, Hill JA, Xie JL, Chen Y-L, Poutanen SM, Rennie RP, Heitman J, Cowen LE. 2012. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog. 8:e1002718. doi:10.1371/journal.ppat.1002718.
32. Hakki M, Staab JF, Marr KA. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
33. Moudgal V, Little T, Boikov D, Vazquez JA. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49:767-769.
34. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
35. Axner-Elings M, Botero-Kleiven S, Jensen RH, Arendrup MC. 2011. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J. Clin. Microbiol. 49:2516-2521.
36. Balashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
37. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
38. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
39. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, Kontoyiannis DP. 2011. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J. Infect. Dis. 204:626-635.
40. Niimi K, Monk BC, a Hirai Hatakenaka K, Umeyama T, Lamping E, Maki K, Tanabe K, Kamimura T, Ikeda F, Uehara Y, Kano R, a Hasegawa Cannon RD, Niimi M. 2010. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J. Antimicrob. Chemother. 65:842-852.